Nivalin (Galantamine Hydrobromide)

Galantamine, the active ingredient in Nivalin, is an acetylcholinesterase inhibitor presented as an injectable formulation for intramuscular, intravenous, and subcutaneous use. It is employed to treat mild to moderate Alzheimer’s disease in adult patients, helping to improve cognitive function by increasing acetylcholine levels in the central nervous system.

GNH USA supplies Nivalin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Galantamine acts on the cholinergic pathway to address cognitive decline in Alzheimer’s disease.

Mild Alzheimer’s disease: modest improvement in memory and attention. Moderate Alzheimer’s disease: stabilization of daily functional abilities. Early‑stage Alzheimer’s disease: delay in disease progression.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes, especially at treatment initiation. - Diarrhea: loose stools that may improve with dose titration. - Loss of appetite: reduced desire to eat. - Dizziness: transient light‑headedness. - Headache: mild tension‑type pain.

Serious or Rare Side Effects: - Bradycardia: significant slowing of heart rate. - Severe vomiting: persistent emesis requiring medical attention. - Elevated liver enzymes: indication of hepatic stress. - Seizures: rare convulsive events. - Anaphylactic reaction: acute allergic response with breathing difficulty.

Before initiating therapy, consider the following safety measures.

Dose titration: start low and increase gradually as tolerated. Renal impairment: adjust dose or monitor renal function closely. Hepatic impairment: use with caution and monitor liver enzymes. Cardiac conduction disorders: obtain baseline ECG and monitor heart rate. Concurrent cholinergic drugs: avoid additive cholinergic effects. Store at ambient temperature: keep in original container, protect from moisture and light.

Galantamine may interact with several medication classes.

Major Interactions (Avoid): - Anticholinergic agents: may reduce therapeutic efficacy. - Beta‑blockers: can exacerbate bradycardia. - CYP2D6 inhibitors (e.g., quinidine): increase galantamine plasma levels.

Moderate Interactions (Monitor Closely): - Other acetylcholinesterase inhibitors: additive cholinergic effects. - SSRIs or other antidepressants: may increase nausea. - Antihistamines: may increase anticholinergic burden.